CST-3056 alpha-1A adrenoceptor agonist program
undiscloseddrug program · high · Fri Sep 12 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Treat neurogenic orthostatic hypotension and advance an alpha-1A adrenoceptor agonist for Alzheimer's disease by restoring adrenergic signaling.
Small-molecule alpha-1A adrenoceptor agonist evaluated in a clinical study for orthostatic symptoms and signs in neurogenic orthostatic hypotension.
ClinicalTrials.gov record for a study evaluating CST-3056 in subjects with neurogenic orthostatic hypotension; strategic investment of up to $5.8 million from the Alzheimer's Drug Discovery Foundation to advance CST-3056 for Alzheimer's disease.
CST-103 clenbuterol plus CST-107 nadolol neurodegenerative disorders program
phase 2drug program · high · Sun Sep 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Assess central nervous system and pharmacodynamic effects of clenbuterol while using nadolol to control peripheral beta-2 adrenoceptor effects in neurodegenerative disorder populations.
Phase II randomized, placebo-controlled, double-blind, crossover study of clenbuterol (CST-103) co-administered with nadolol (CST-107); cerebral blood flow and cognitive-function studies of beta-adrenoceptor acting drugs including clenbuterol.
2024 publications reported clenbuterol-related cerebral blood flow increases and pro-cognitive effects in healthy volunteers, with trends or observed effects in Parkinson's disease, mild cognitive impairment, or related neurodegenerative populations.
Single doses of clenbuterol produced dose-dependent increases in regional cerebral blood flow in multiple brain regions, including hippocampus, amygdala, and thalamus, and were safe and well tolerated. Separate cognitive testing found clenbuterol improved adaptive tracking and immediate verbal recall in healthy volunteers, with trends toward improved recall in Parkinson's disease patients.
CST-103 plus CST-107 Parkinson's disease freezing-of-gait program
phase 2drug program · high · Sat Jun 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Evaluate whether CST-103 co-administered with CST-107 improves freezing-of-gait symptoms in subjects with Parkinson's disease.
Phase II randomized, placebo-controlled, double-blind, crossover study of multiple oral doses of CST-103 in the presence of CST-107.
Phase II clinical trial record for CST-103 co-administered with CST-107 in Parkinson's disease subjects with freezing of gait.
CST-2032 plus CST-107 cognition program in Parkinson's and Alzheimer's disease
phase 2drug program · high · Mon Apr 11 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Evaluate effects of CST-2032 administered with CST-107 on cognition in participants with mild cognitive impairment or mild dementia due to Parkinson's disease or Alzheimer's disease.
Phase 2a randomized, placebo-controlled, double-blind, crossover study of CST-2032 administered with CST-107.
Phase 2a clinical trial record in mild cognitive impairment or mild dementia due to Parkinson's or Alzheimer's disease.
CST-2032 plus CST-107 cognitive impairment cerebral perfusion/metabolism study
undiscloseddrug program · high · Fri Oct 01 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Evaluate CST-2032 with pre-administered CST-107 for safety, tolerability, cognition, cerebral perfusion, and cerebral metabolism in patients with cognitive impairment.
Clinical study measuring safety, tolerability, cognition, cerebral perfusion, and cerebral metabolism after CST-2032 with pre-administered CST-107.
ClinicalTrials.gov record for CST-2032 in subjects with cognitive impairment.
CuraAX
undiscloseddrug program · medium
Pipeline program within CuraSen's small-molecule adrenergic signaling restoration approach.
Adrenergic receptor agonist or noradrenergic restoration small-molecule approach; specific target and indication not disclosed in supplied material.
Listed on CuraSen's pipeline.
CuraCN
undiscloseddrug program · medium
Pipeline program within CuraSen's small-molecule adrenergic signaling restoration approach.
Adrenergic receptor agonist or noradrenergic restoration small-molecule approach; specific target and indication not disclosed in supplied material.
Listed on CuraSen's pipeline.
CuraXN
undiscloseddrug program · medium
Pipeline program within CuraSen's small-molecule adrenergic signaling restoration approach.
Adrenergic receptor agonist or noradrenergic restoration small-molecule approach; specific target and indication not disclosed in supplied material.
Listed on CuraSen's pipeline.
